100% Quality Guarantee
PhD-Level Technical Support
Human IGHE (FB825) Antibody - SDS-PAGE
Key Features

Human IGHE (FB825) Antibody (GXBS01599)

SKU GXBS01599
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Human
Reactivity Human
Applications ELISA, FCM, Functional assay, Research in vivo
Clone ID FB825
Isotype IgG
$677 - $2,208

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human IGHE (FB825) Antibody

Human IGHE (FB825) Antibody is a research-grade biosimilar monoclonal antibody targeting Ig epsilon chain C region. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

Immunoglobulin heavy constant epsilon (IgE/IGHE) is a ~59 kDa protein. Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose